Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
MIT engineers have created injectable "mini livers" — tiny clusters of liver cells and hydrogel microspheres that can be delivered via syringe and survive inside the body for months. In mouse studies, the grafts connected to blood vessels, stayed alive for at least eight weeks, and kept producing key liver proteins. The innovation could one day serve as a bridge to transplantation or even an alternative to surgery for the 10,000+ Americans waiting for a donor liver.
MIT engineers have developed injectable "mini livers" — a potential new way to support patients whose livers are failing without requiring major surgery. The approach combines live hepatocytes (the liver's workhorse cells) with tiny hydrogel microspheres and supportive fibroblast cells into a mixture that flows through a syringe but solidifies once inside the body, forming a stable tissue graft.
In mouse studies, the grafts were injected into abdominal fatty tissue, where blood vessels gradually grew in to nourish the transplanted cells. The hepatocytes survived for the full eight-week study period and continued releasing liver-specific proteins into circulation — a strong sign the "satellite livers" were actually functioning. Ultrasound guidance was used both to deliver and monitor the implants non-invasively.
Key Takeaways:
Why it matters: Liver transplants are life-saving but scarce and surgically demanding. Injectable mini livers could expand treatment options for patients who can't wait — or can't withstand — a full transplant, potentially transforming how chronic liver disease is managed.
